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Abstract
Objective—Data on the prevalence of birth defects and neural tube defects (NTD) in Latin 
America are limited. The present review summarizes NTD prevalence and time trends in Latin 
American countries and compares pre- and post-fortification periods to assess the impact of folic 
acid fortification in these countries.
Design—We carried out a literature review of studies and institutional reports published between 
1990 and 2010 that contained information on NTD prevalence in Latin America.
Results—NTD prevalence in Latin American countries varied from 0.2 to 9.6 per 1000 live 
births and was influenced by methods of ascertainment. Time trends from Bogota, Costa Rica, 
Dominican Republic, Guatemala City, México and Puerto Rico showed average annual declines of 
2.5% to 21.8%. Pre- and post-fortification comparisons were available for Argentina, Brazil, 
Chile, Costa Rica, Puerto Rico and México. The aggregate percentage decline in NTD prevalence 
ranged from 33% to 59%.
Conclusions—The present publication is the first to review data on time trends and the impact 
of folic acid fortification on NTD prevalence in Latin America. Reported NTD prevalence varied 
markedly by geographic region and in some areas of Latin America was among the lowest in the 
world, while in other areas it was among the highest. For countries with available information, 
time trends showed significant declines in NTD prevalence and these declines were greater in 
countries where folic acid fortification of staples reached the majority of the population at risk, 
such as Chile and Costa Rica.
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Birth defects, including neural tube defects (NTD), are one of the leading causes of infant 
and neonatal mortality in countries undergoing an epidemiological transition because of 
declines in infant mortality and improvements in the environment(1). Globally, NTD 
prevalence is estimated to be over 300 000 new cases per annum, with over 40 000 deaths 
and 2.3 million disability-adjusted life years (2). Further, in low-income countries, 17% to 
70% of neonatal deaths from birth defects are attributed to NTD (3). However, scanty and 
fragmented surveillance information hinders the ability to adequately determine the 
prevalence of NTD in more than 11 million births per year in Latin America (4). Birth 
defects surveillance information is vital for monitoring and evaluating the impact of 
prevention and intervention programs.
Observational studies reinforce the evidence from clinical trials that have shown 
conclusively that consumption of staples fortified with folic acid and adequate 
periconceptional folic acid supplementation reduce the risk of NTD (3,5–7). Currently, all 
Latin American countries except Venezuela have mandatory fortification legislation 
and .programs aimed at decreasing conditions related to deficiencies of folic acid and other 
micronutrients. Few countries, however, have established monitoring and evaluation 
components to assess the impact of their NTD prevention programs and fewer still have 
identified time trends pre- and post-fortification (8).
The present review had two main objectives: (i) to summarize NTD prevalence and time 
trend data in Latin American countries; and (ii) to compare pre- and post-fortification 
periods to assess the impact of folic acid fortification on NTD prevalence in these countries.
Methods
We carried out a review of studies published between 1990 and 2010 to identify reports 
containing information on NTD prevalence and, when appropriate, the time periods in which 
fortification programs were initiated. We searched CINAHL, Cochrane Collaboration, 
EMBASE, Global Health, Google Scholar, Ingenta, Medline, the Pan-American Health 
Organization search engine, PubMed, Red de Revistas Científicas de America Latina y el 
Caribe, España y Portugal, Revista Médica de Chile, the Latin American and Caribbean 
Health Sciences Literature (LILACS) and Web of Science for published information. The 
review was conducted between March 2007 and December 2010. The titles and abstracts 
were reviewed to determine if the content was related to NTD prevalence and/or folic acid 
fortification in the region. Studies identified for potential inclusion were assessed by two of 
the co-authors.
We considered for inclusion observational studies (cohort, case–control, cross-sectional and 
ecological studies) that included the following information: a clear description of the study 
population and methods (case definition and methods of case ascertainment, demographics); 
diagnosis of NTD in live-born infants in the first year of life and in stillbirths; population 
setting (clinic, hospital or population derived); number of type-specific cases and/or total 
cases; prevalence rates or ratios; limitations and biases; and any information regarding folic 
acid fortification interventions, when available. Studies were scored independently by two of 
the co-authors based on the following aspects of study quality: (i) clarity of case definition; 
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(ii) methods of case ascertainment; (iii) reported prevalence rates or ratios; (iv) number of 
live births; (v) study limitations; and (vi) biases. Each category contributed one point. The 
scores of each independent reviewer were averaged, and the articles or reports were then 
classified based on their total score as ‘very good’ (score=5–6), ‘good’ (score=3–4), 
‘satisfactory’ (score=2) or ‘poor’ (score=0–1). Only studies classified as good or very good 
were included in the review.
We excluded publications with fewer than 5000 live births per year; those that did not report 
the number of cases or reported the NTD prevalence without inclusion of the total number of 
births; those that reported graphs without point estimates; publications in which the 
information was based on mortality only; and/or publications that included only one type of 
NTD (i.e. anencephaly or spina bifida or encephalocele). Publications containing total NTD 
cases only were included when the methodology specifically defined at least two forms of 
NTD.
Most of the publications on NTD used data from national or regional registries and 
surveillance/vital statistics systems. The registries cited most often were the Latin American 
Collaborative Study of Congenital Malformations (ECLAMC) (9), the Costa Rica 
Congenital Malformations Registry (CARCM)(10), the Cuban Congenital Malformations 
Registry (RECUMAC)(11), the Mexican External Malformations Epidemiological 
Surveillance Registry (RYVEMCE)(12) and the Puerto Rico Congenital Malformations 
Surveillance Systems(13). In addition, reports from Argentina, Brazil and México also used 
data sources based on national or local hospital discharge data (14–16). Additionally, we 
included information from institutional reports published by the Universidad de San Carlos 
in Guatemala, the Costa Rica Ministry of Health, the Dominican Republic Ministry of 
Health and the Fundación de Niños Saludables in Honduras.
Analysis
To increase stability of the NTD prevalence estimates, we grouped years of reported cases 
and births when possible. Time trends were estimated from those publications that provided 
at least four time points. We present basic trends in prevalence by computing prevalences 
(with 95% confidence intervals) of NTD over time within source using exact Poisson limits 
(17,18). We analyzed basic time trends using Poisson and negative binomial distribution 
models for each source separately:
where NTD is the case count and LB is the live birth count. Results of the model provided a 
summary of temporal trends as prevalence ratios, expressed as relative changes in 
prevalence per unit changes in time.
The impact of fortification was evaluated by comparing prevalences before and after the 
onset of fortification. The most basic comparison was the calculation of a single prevalence 
rate ratio (PRR)(19,20), with approximate limits for 95% confidence:
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For countries with sufficient data for both pre- and post-fortification periods, we used a 
more complex model:
whose term β fort x year gives a basis for a test of change in trend across fortification. 
Additionally, judicious use of the β fort and β year terms allowed estimation of trends for both 
pre- and post-fortification periods. SAS GENMOD version 9.2 software was used to 
produce all estimations and standard errors (21).
Results
Search results
The search identified a total of 2457 citations published from January 1990 to December 
2010. Of these, 2295 were excluded because they duplicated data from original reports or 
were commentaries on previously published data. Of the remaining 162 citations, thirty 
three were excluded because reports could not be located after extensive library and 
electronic searches as well as three or more unsuccessful attempts to contact the authors. 
Another sixty-five were excluded after reading the abstract and/or full text because the 
reports did not include specific NTD information, included only one type of NTD, or had a 
denominator of less than 5000 live births. This process identified a total of sixty-four 
reports. In addition, we included data from five institutional reports, two of which were 
published by the Universidad de San Carlos in Guatemala and one each by the Costa Rica 
Ministry of Health, the Dominican Republic Ministry of Health and the Proyecto Niños 
Saludables in Honduras. Of the sixty-nine reports that satisfied the inclusion criteria, fifty-
one (73.9%) were published in peer-reviewed journals. Table 1 summarizes the studies 
included in the present review by country, study design, time period covered, data sources, 
number of NTD cases by type and total, number of live births, and prevalence of NTD per 
1000 live births by type and total.
Reports were available from fifteen countries and one sub-region. Information was not 
available for Bolivia, El Salvador, Nicaragua and Panama, and although Paraguay reported 
NTD prevalence, its birth cohort was too small to satisfy our inclusion criteria.
Within each country, the data, which covered single or multiple locations and different time 
periods and hospitals, varied by methodology used and geographic areas covered. Data for 
most countries covered regional and/or local areas; however, data for Argentina, Costa Rica, 
Cuba and Puerto Rico were also collected at the national level. ECLAMC reported NTD 
prevalence for South America and several locations in the subcontinent. In a majority of 
reports, spina bifida cases were the largest contributor to total NTD cases.
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Among the sixty-nine reports, forty-two (60.9%) were based on hospital registries 
(structured case definition and inclusion criteria), fourteen (20.3%) on review of medical 
records, seven (10.1%) on hospital discharge data and the remaining six (8.7%) were based 
on population-based registries, review of hospital delivery logs or reports from live birth 
surveillance systems. Costa Rica, Cuba and Puerto Rico also included reports from specialty 
clinics to capture post-discharge diagnoses. In addition, data from Cuba included pregnancy 
terminations.
Prevalence of neural tube defects
Reported NTD prevalence by country or location (Table 1) showed wide geographic 
variation within and between countries, ranging from 0.2 to 9.6 per 1000 live births.
National prevalence estimates
National NTD prevalence estimates were available for seven countries: Argentina, Costa 
Rica, Cuba, Ecuador, Guatemala, México and Puerto Rico. These estimates varied by 
country and methodology. National registry data showed that NTD prevalence per 1000 live 
births was 0.45 in Costa Rica (2007)(22), 1.10 in Cuba (2005–2006)(23), 0.82 in Ecuador 
(2001–2005)(24) and 0.90 in Puerto Rico (2008)(25). National hospital discharge data 
showed an NTD prevalence of 1.62 in Argentina (2005)(15) and 0.47 in México (2004)(26). 
NTD prevalence based on national hospital delivery logs was 2.82 in Guatemala (2001–
2003)(27).
Regional and local prevalence estimates
Hospital-based registry data have been used to estimate NTD prevalence in specific 
locations in different countries. For example, Argentina hospital registry data from fifty-nine 
hospitals in seven regions showed an NTD prevalence of 1.99 per 1000 live births for the 
period 1994–2007(28). This prevalence is consistent with another hospital registry study in 
forty-one Argentinean hospitals, which showed that the prevalence of NTD for 1982–2007 
was 2.01 per 1000(29). Available hospital registry data from Chile in 1998–2000 showed a 
similar prevalence. However, NTD prevalence estimates based on hospital registry data 
varied within and between locations in Brazil, Colombia, Cuba, México, Uruguay and 
Venezuela. For example, Brazilian hospital registry data from nineteen ECLAMC-
participating hospitals for the periods 2003–2005 and 2005–2007 showed that NTD 
prevalence was 4.51 and 3.80 per 1000, respectively (29). This NTD prevalence was almost 
half the 9.60/1000 prevalence reported from Porto Alegre for the time period 2000–
2005(30). In contrast, NTD prevalence in hospital registry data from Minais Gerais and Sao 
Paulo for comparable time periods ranged from 1.13 to 4.87 per 1000 live births (16,31).
Variations in NTD prevalence estimates were also observed between hospital delivery logs 
and hospital records data in several locations. For example, hospital delivery log data from 
two Guatemala City hospitals in 2004–2008 showed an NTD prevalence of 2.00 per 1000 
live births(32), compared with 3.47 per 1000 in 2004–2005 identified in data derived from 
hospital records at the same hospitals (33).
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Time trends in prevalence of neural tube defects
Information to assess NTD prevalence time trends was available for Bogota (Colombia), 
Costa Rica, Cuba, Dominican Republic, Guatemala City (Guatemala), México (RYVEMCE) 
and Puerto Rico. Overall time trends of NTD prevalence exhibited average annual declines 
ranging from 2.5% to 21.8 % (Table 2), with the exception of Cuba, which showed an 
increase; however, it was not possible to model the trend prevalence because the Cuban 
surveillance system changed its inclusion criteria for the period 2000–2004.
Fortification
All Latin American countries have mandatory folic acid fortification of wheat flour except 
Venezuela (Table 3). Fortification levels range from 0.35mg/kg to 3.3mg/kg. While most 
countries started fortification in the late 1990s, Argentina, Brazil, Peru and Uruguay 
introduced fortification regulation in 2002, 2002, 2004 and 2006, respectively (34–37). In 
addition, México also fortifies corn flour and Costa Rica also fortifies corn flour, rice and 
milk (34,38).
Argentina, Brazil, Chile, Costa Rica, Cuba, Puerto Rico and México were the only countries 
for which information was available to perform a meaningful comparison of changes in pre- 
and post-fortification NTD prevalence. We directly compared NTD prevalence between 
these periods by computing NTD prevalence for years pooled pre and post-fortification, 
summarizing effects as a prevalence ratio with 95% confidence limits. Table 4 depicts the 
post-fortification changes in NTD prevalence and their corresponding PRR and 95% CI for 
Argentina, Brazil, Chile, Costa Rica, Cuba, México (RYVEMCE) and Puerto Rico. All sites 
showed significant declines in NTD prevalence ranging from 33.0% to 59.0%. In the case of 
Costa Rica we were able to fit a more complex model including an interaction term to assess 
whether the NTD secular trend changed after fortification. Our model yielded a statistically 
significant interaction term (P<0.03) suggesting that NTD prevalence changed significantly 
following fortification. The pre-fortification prevalence was estimated at 1% decline (95% 
CI 24%, 13%) per year, and the post-fortification trend was estimated at 6% decline (95% 
CI 210.2%, 2.1%) per year.
Discussion
To our knowledge, the present publication is the first one that reviews data on NTD 
prevalence in Latin America, including time trends and the impact of folic acid fortification. 
The majority of countries showed a generalized decrease in the NTD prevalence in time, 
similar to time trend declines previously reported elsewhere (39–41).
Our review showed that fifteen countries reported local and/or regional NTD prevalence and 
seven of them reported, in addition, national prevalence of NTD. Comparisons of NTD 
prevalence between and within countries showed regional and/or local differences, most 
probably due to variations in data collection methods. In our review, the main data 
collection methods used to estimate NTD prevalence were hospital-based registries, clinical 
examination at birth and review of hospital records, hospital discharge data, hospital 
delivery logs and live birth statistics. Hospital-based registries have defined inclusion and 
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exclusion criteria and clear diagnostic criteria including specific definitions for case 
ascertainment and information recording. Hospital clinical examinations at birth can be as 
effective as hospital registries in recording numbers and types of NTD, if there are in place 
specific protocols for diagnostic criteria, case inclusion and exclusion, and case 
ascertainment. However, hospital clinical examinations without specific protocols are more 
susceptible to biases than registries or structured surveillance systems because these 
examinations are not standardized and clinicians have differences in case definition, 
differences in how newborns are examined and differences in how results are recorded. 
Similarly, hospital discharge data are more susceptible to biases due to differences in criteria 
within and across hospitals and physicians related to case ascertainment, case recording and 
ICD (International Classification of Diseases) code assignment in the discharge diagnosis 
fields. Also, hospital discharge data are susceptible to including multiple records of the same 
individual and hospital transfers or readmissions, and might contain records of patients who 
do not belong to the hospital catchment area. In addition to being susceptible to differences 
in hospitals and medical practices, hospital delivery logs are limited because they do not 
include cause-specific morbidity or mortality. In addition, NTD are serious defects with a 
very high mortality and it is essential to count stillbirths when estimating the prevalence of 
NTD to avoid an underestimation of prevalence.
In summary, hospital-based data, although readily available in many countries, also reflect 
variations in access to and utilization of health services. The impact of different data 
collection methods and sources of information on NTD prevalence estimates has been 
reported previously (42–46).
Differences in NTD prevalence by country can also be explained by geographic variation. 
For example, higher NTD prevalence in some areas of Brazil, Guatemala, Honduras and 
México is consistent with higher levels of poverty, higher conception rates for younger 
mothers, and less access to health services and fortified staples(47,48). In contrast, the 
observed increase in Cuba’s NTD prevalence trend was most likely due to differential 
ascertainment: changes in inclusion criteria, increase in number of participating hospitals 
and inclusion of pregnancy terminations (49).
Nevertheless, despite data limitations and geographic variation, these data are important 
because they can show changes over time.
Fortification
Comparisons between pre- and post-fortification prevalence of NTD showed that 
fortification efforts were effective in reducing NTD prevalence in Argentina, Bogota 
(Colombia), Chile, Costa Rica, Guatemala City (Guatemala), México (RYVEMCE) and 
Puerto Rico. This confirms the reduction in NTD prevalence reported elsewhere after 
fortification with folic acid (41,50–55) and the previous declines in NTD prevalence 
reported in the region (29,52,53).
A declining secular trend that started before the implementation of fortification .programs 
may obscure assessment of the NTD prevention effect of these .programs. Previous 
publications have reported techniques that include methodological approaches to assess the 
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potential effects attributable to fortification when a previous declining trend has been 
identified (56). Using a methodology similar to that reported by Chen et al. (56) we 
attempted to determine the pre- and post-fortification slopes that represented summaries of 
the annual NTD prevalence before and after implementation of fortification. However, the 
only data set in which we could evaluate such changes was from Costa Rica because we had 
enough data to assess the pre- and post-fortification trend. For the pre-fortification period 
the slope of NTD prevalence was not different from zero; however, the post-fortification 
period showed a significant decline in NTD prevalence. This result re-confirms that the 
decline in NTD prevalence can be accelerated when countries select staples that are highly 
consumed by the population and monitor and evaluate the levels of folic acid in fortified 
staples and the impact of their fortification .programs. The present review re-asserts that 
fortification of staples with folic acid results in up to a 59% decrease in NTD cases that 
could result in reductions in mortality, morbidity and financial burden associated with these 
conditions (57,58).
Limitations
There are several limitations that could have a bearing on our findings regarding NTD 
prevalence in Latin America. The overall quality of the review and its results is dependent 
on the quality of information of the individual studies. The heterogeneity of case 
ascertainment and years of study across countries and across surveillance .programs affected 
our ability to pool estimates, make direct comparisons or quantitatively evaluate trends 
across time or countries. The use of voluntary hospital-based surveillance systems that 
capture only a proportion of the population at risk is also a potential limitation of the study. 
The under-representation of rural populations in the reported data from some countries can 
affect estimates.
Conclusion
The present publication is the first to review and report data on NTD prevalence in Latin 
America including time trends and the impact of folic acid fortification. The surveillance of 
NTD in Latin America is currently limited because few countries have established systems 
to report national and local NTD prevalence. However, when data are available, reported 
NTD prevalence, which varies by geographic region from 0.2 to 9.6 per 1000 live births, is 
in some areas of Latin America among the lowest in the world while in others is among the 
highest. Observed declines in NTD prevalence were largest in countries where folic acid 
fortification of staples reached the majority of the population at risk, such as Chile and Costa 
Rica. NTD prevalence among countries in which fortification had been implemented 
showed declines ranging from 33.0% to 59.0%. It was possible to show that fortification has 
an impact and was consistent for most countries. Selected registries in the region have 
become proxies for national surveillance systems, and even though they have limited 
coverage, they constitute the major source of information regarding NTD prevalence and 
time trends that allow for the monitoring of disease burden and impact of 
fortification .programs. The need for adequate data is central to a better understanding of the 
magnitude of the public health impact of NTD in the Latin American region and the 
assessment of the effectiveness of prevention .programs. The implementation of national 
NTD surveillance .programs could help to close this information gap.
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